Anavex life sciences announces late-breaking presentation of phase 2b/3 data of oral anavex®2-73 (blarcamesine) for early alzheimer's disease at the upcoming clinical trials on alzheimer's disease (ctad) congress 2022

New york, oct. 17, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that the company will present phase 2b/3 anavex®2-73-ad-004 data of oral anavex®2-73 (blarcamesine) for early alzheimer's disease at the upcoming clinical trials on alzheimer's disease (ctad) congress 2022 in san francisco, ca and publish the findings in a peer-reviewed medical journal.
AVXL Ratings Summary
AVXL Quant Ranking